Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05120830 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05120830 · ClinicalTrials.gov record · last posted 2026-03-24

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Study acronym: NTLA-2002
StatusActive, Not Recruiting
PhasePhase 1/2
Started2021-12-10
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Amendment record 11 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 11 times since 2021-11-12; most recent amendment 2026-03-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-03-07
Status change Recruiting→Active, Not Recruitingv7
2021-11-17
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05120830
Lead Sponsor Intellia Therapeutics
Conditions Hereditary Angioedema
Enrollment 37 participants
Start Date 2021-12-10
Primary Completion 2024-04-04 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-24